Piper Sandler Logs Significant Q1 Bank M&A, Equity Share and Debt Advisory Strength
Piper Sandler closed significant Q1 bank M&A deals despite slower large transactions and saw its busy derivatives desk execute increased hedging amid rate volatility. The firm gained outsized equity capital markets share in healthcare and posted strong debt capital markets advisory results but warned Q1 share and fees may slip.
1. Bank M&A and Derivatives
In Q1 Piper Sandler closed a significant number of bank M&A transactions, noting a slight slowdown among larger deals but continued volume in smaller ones. Its derivatives desk reported heightened activity, completing an increased number of hedging transactions as clients navigated volatile forward-rate curves.
2. Equity Capital Markets Performance
The firm captured outsized market share in equity capital markets, driven largely by healthcare and biotech deal flow. While first-quarter capital market conditions remained favorable, leadership expects share to normalize in Q2 due to the difficulty of sustaining multiple large fees.
3. Advisory Fee Outlook
Advisory fees are anticipated to decline sequentially as choppy macro conditions temper sponsor transactions and bank deal announcements. The company highlighted exceptional performance in healthcare and MedTech advisory during Q1 but forecasts moderation across other sectors until sponsor urgency picks up.
4. Non-M&A and Debt Capital Markets
Non-M&A advisory posted strong results, with debt capital markets advisory delivering an outsized performance that outpaced restructuring and private capital advisory. Management expressed confidence in continued momentum from recent private capital advisory acquisitions while remaining cautious on broader transaction pacing.